Please login to the form below

Not currently logged in
Email:
Password:

Cosentyx

This page shows the latest Cosentyx news and features for those working in and with pharma, biotech and healthcare.

Novartis buys cancer specialist Endocyte for $2.1bn

psoriasis drug Cosentyx (secukinumab) and Entresto (sacubitril/valsartan) for heart failure – up 37% to $750m and 113% to $271m, respectively – as well as Sandoz’biosimilar drugs.

Latest news

More from news
Approximately 20 fully matching, plus 45 partially matching documents found.

Latest Intelligence

  • Can value-based healthcare take off and reach for the skies? Can value-based healthcare take off and reach for the skies?

    costs. It was then backed with a ‘no response-no payment’contract. It has also struck novel reimbursement packages with its heart failure therapy Entresto and its psoriasis treatment Cosentyx.

  • The good, the bad and the ugly The good, the bad and the ugly

    Similarly, Novartis has enjoyed 31.7% growth thanks to another psoriasis/psoriatic arthritis treatment - Cosentyx - while GSK’s lupus therapy, Benlysta, has helped it increase immunology revenues by almost 45%.”.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
COUCH.

WE ARE COUCH – a full service medical communications agency. We are a trusted partner; always striving to help make...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics